Q-omics provides the consensus-scored FOXD2 profile across patient tissues and cancer cell-line models. FOXD2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FOXD2 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, FOXD2 RNA expression shows 18,262 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, COAD, and UVM as cancer lineages where FOXD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXD2 survival associations across molecular data types. FOXD2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXD2 RNA expression–survival associations across cancer types. High FOXD2 expression shows unfavorable associations in KIRP, UVM, KICH, HNSC and LGG, but favorable associations in STAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FOXD2 RNA expression.
This table summarizes FOXD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FOXD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXD2 shows lower tumor expression in COAD and higher tumor expression in HNSC, BLCA, THCA, STAD and LUAD. The COAD box plot shows higher FOXD2 RNA expression in normal versus tumor tissue (log2 FC = −1.754, t-test p < 0.001).
This table shows molecular features associated with FOXD2 in patient tissues and cancer cell lines. In patient samples, FOXD2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
